Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Napster Co-Founder Funds Immunotherapy Research Project

By Drug Discovery Trends Editor | April 14, 2016

Parker (left) made a generous donation to cancer research. (Credit: The Parker Institute)Sean Parker, the entrepreneur behind music-sharing service Napster, is providing a $250 million grant to support a consortium aimed at supporting immunotherapy research.

This venture, a non-profit named the Parker Institute for Cancer Immunotherapy, will bring together more than 300 scientists from six major academic cancer research centers, according to The Washington Post. Stanford, Memorial Sloan Kettering Cancer Center, and the University of Pennsylvania are some of the members taking part in this endeavor.

One member from each of the participating institutions will constitute a steering committee, which will establish the group’s research agenda as well as enable better collection of data and clinical trials across all of the involved labs.

It’s a similar strategy being implemented in Vice President Joe Biden’s Cancer Moonshot. A key tenet of this initiative is to “break down silos” regarding communication between the public and private sectors as a way to find a cure for these diseases.

Plus, The Washington Post noted another unique innovation of Parker’s project is that the team will retain ownership of the intellectual property while taking charge on licensing and negotiating potential market opportunities with drugmakers.

Parker provided this money because he felt immunotherapy research “is at a turning point and would benefit from research that is done without regard for its costs,” reported USA Today.

This class of drugs essentially activates the body’s immune system in order to combat foreign pathogens. Early studies have shown these treatments have promise, but more research needs to be done to ensure these drugs can work on a large group of patients and are cost-effective.

R&D 100 AWARD ENTRIES NOW OPEN:

Establish your company as a technology leader! For more than 50 years, the R&D 100 Awards have showcased new products of technological significance. You can join this exclusive community!  Learn more.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50